Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis.

This short monograph describes a trial of interferon beta-1b in patients with primary progressive multiple sclerosis (PPMS) or transitional MS. Designed as a randomized, placebo-controlled pilot, the trial randomly placed 73 eligible patients into two groups, placebo or interferon beta-1b 8 MIU given subcutaneously every other day for two years. Significant differences favouring interferon beta-1b in the MSFC score, T2 lesion volume and TI lesion volume at 24 months were observed. Further study of interferon beta-Ib therapy in PPMS patients in warranted.
AuthorsXavier Montalban
JournalMultiple sclerosis (Houndmills, Basingstoke, England) (Mult Scler) Vol. 10 Suppl 1 Pg. S62; discussion 62-4 (Jun 2004) ISSN: 1352-4585 [Print] England
PMID15218812 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Review)
Chemical References
  • Adjuvants, Immunologic
  • Interferon beta-1b
  • Interferon-beta
  • Adjuvants, Immunologic (therapeutic use)
  • Europe
  • Humans
  • Interferon beta-1b
  • Interferon-beta (therapeutic use)
  • Multiple Sclerosis, Chronic Progressive (drug therapy)
  • Pilot Projects

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: